SCHEMBL15545847

SCHEMBL15545847

CC(C)(Oc1cccc(F)c1)C(=O)Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
PPARA Q07869 4/20 0.40
HPGD P15428 1/20 0.40
PPARD Q03181 1/20 0.40
PPARG P37231 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAOB P27338 1/20 0.38
SSTR4 P31391 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373353 0.85 PPARA (0.54) CNR1CNR2POLBPPARAPPARD
SCHEMBL11570378 0.81 LMNA (0.51) LMNAPOLBPPARAPPARGMAPT
SCHEMBL9588829 0.81 HSD11B1 (0.49) CNR1CNR2POLBPPARAPPARG
SCHEMBL11570463 0.81 KDM4E (0.50) LMNAPOLBPPARAPPARGMRGPRX4
SCHEMBL7994910 0.80 CNR1 (0.48) CNR1CNR2ESR1ESR2NPC1
SCHEMBL11550869 0.79 PPARA (0.50) CNR1LMNAPPARAHPGDPPARD
SCHEMBL7988059 0.78 PPARA (0.61) CNR1CNR2LMNAPOLBPPARA
SCHEMBL1805865 0.78 PPARA (0.53) LMNAPOLBPPARAPPARDPPARG
SCHEMBL10294030 0.76 NFE2L2 (0.43) ESR1ESR2NPC1RAB9APPARA
SCHEMBL16144539 0.74 MAOB (0.42) ESR1ESR2PPARAPPARGMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875001-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO LTD (CN) 2019-01-09 EP disclosed
US-9434695-B2 Nitrogenous heterocyclic derivatives and their application in drugs SUNSHINE LAKE PHARMA CO., LTD (CN) 2016-09-06 US disclosed
EP-2875001-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS Sunshine Lake Pharma Co., Ltd. (CN) 2015-05-27 EP disclosed
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-26 US disclosed
WO-2014012360-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs TNNC1, TNNI3, IAPP CNR1 2084/4885CNR2 1998/4885ESR1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.